• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® ADPR Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • CD38 Assay System
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human CD38 Enzyme
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay System
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • p97 Assays – Application
      • Ketohexokinase Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
      • WRN Exonuclease Assays – Application
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Newly Patented Aurora A Kinase Inhibitor a Promising Contender for Cancer Treatment

by Bellbrook Labs / Wednesday, 15 November 2017 / Published in HTS Assays, News, Products, Success Stories

Aurora A Kinase in Cancer Drug Development

Aurora A Kinase, along with -B and -C, are members of a family of serine/threonine protein kinases that play critical roles in coordinating mitosis, including establishment of the mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. The enzyme’s role in coordinating mitotic events is intricately regulated through phosphorylation, dephosphorylation, and degradation.1

Aurora A Kinase Inhibitor - 3D Illustration of Cell Division

Aurora A is able to phosphorylate diverse substrates, making it vital in regulating spindle fiber alignment of chromosomes in anaphase for normal centrosome separation.

Aurora-A is frequently overexpressed in cancers, and its dysregulation is believed to drive tumorigenesis by causing chromosomal instability and tumor cell heterogeneity 2,3 Research on abnormal Aurora A kinase levels have shown centrosome amplification, aneuploidy from failure in cytokinesis, and cell transformation in cases of over-expression which can be linked to carcinogenesis and tumorigenesis.3

Though the first Aurora kinase inhibitor, alisertib, entered the clinic several years ago, success has been limited possibly because of inhibition of Aurora B and C as well as off-target effects on unrelated proteins.  In an effort to overcome these specificity issues, a group at Eli Lilly, led by James Henry, used Bellbrook’s Transcreener assay to facilitate development of an aminopyridine that inhibits Aurora A kinase with an IC50 of 1.12 nM, and is more than 1000-fold less potent for Aurora B.4

Moving Forward: Applications of Aurora A Kinase Inhibition

Very recent studies have revealed that Aurora A acts as a positive regulator of the Yes-associated protein (YAP), a downstream effector in the Hippo pathway, which regulates tissue homeostasis and organ size during development.

Aurora A Kinase Inhibitor - Glioblastoma brain cancer cells under microscope

Inhibition of Aurora A Kinase in glioblastoma-initiating cells is a promising strategy for reducing tumor recurrence.

The study determined that Aurora A kinase acts as a positive regulator of YAP-mediated transcriptional machinery primarily in the nucleus. The functional relevance of this newly discovered regulatory axis is found to be highly correlated with triple-negative breast cancer, suggesting that an inhibitor for Aurora A will be valuable in similar cancers.5

Additionally, Aurora A kinase plays an unexpected role in systematic tumor recurrences of glioblastoma, which opens new possibilities for selective inhibitors in treating one of the deadliest cancers.6

Visit the Eli Lilly & Co website to explore their drug development pipeline. Find out more about how the high throughput screening (HTS) assays work on BellBrook’s kinase assay page.

Learn More About the Transcreener Kinase Assay

References

  1. Carmena, Mar, and William C. Earnshaw. “The cellular geography of aurora kinases.” Nature Reviews Molecular Cell Biology, vol. 4, no. 11, 2003, pp. 842–854., doi:10.1038/nrm1245. https://www.nature.com/articles/nrm1245
  2. Dobson T, Chen J, Krushel LA. Dysregulating IRES-dependent translation contributes to over-expression of the Aurora A kinase onco-protein. Mol Cancer Res (2013) 11(8):887–900.10.1158/1541-7786.MCR-12-0707. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109694/
  3. D’Assoro, Antonino B., et al. “Aurora-A Kinase as a Promising Therapeutic Target in Cancer.” Frontiers in Oncology, vol. 5, June 2016, doi:10.3389/fonc.2015.00295. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701905/
  4. Henry, James Robert, and Eli Lilly And Company. Aurora A Kinase Inhibitor. 2 May 2017. https://www.google.com/patents/US9637474
  5. Chang, S-S, et al. “Aurora A Kinase Activates YAP Signaling in Triple-Negative Breast Cancer.” Oncogene, vol. 36, 2017, pp. 1265–1275., doi:10.1038/onc.2016.292. https://www.nature.com/articles/onc2016292
  6. Willems, Estelle, et al. “The Unexpected Roles of Aurora A Kinase in Glioblastoma Recurrences.” Targeted Oncology, vol. 12, no. 1, 2016, pp. 11–18., doi:10.1007/s11523-016-0457 2. https://link.springer.com/article/10.1007%2Fs11523-016-0457-2
Tagged under: Assay Development Services, drug discovery services, kinase assay, Lead Discovery Services, Transcreener ADP Kinase Assay

What you can read next

Transcreener Assay Helps Find New Approach to C. difficile
BellBrook Labs Introduces the Transcreener™ UGT Far Red Assay
BellBrook Labs Awarded Wisconsin Development Fund

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Preview of DNA Damage Repair Webinar

    [Webinar] Targeting DNA Damage Repair for Drug Discovery Using the Transcreener ADPR® Assay

    Interested in DNA damage repair pathways for dr...
  • Calculating MAPK14 Residence Time

    Transcreener® ADP2 Assay Delivers Precise Measurement of Functional MAPK14 Residence Time

    Researchers at the University of Tubingen use T...
  • DDX1 as a versatile RNA Helicase

    DDX1: A Versatile RNA Helicase

    DDX1 (Dead-Box Helicase 1) belongs to the DEAD-...
  • RAB2 Transports Membrane Bound Vesicles

    Investigating RAB2 as a Vesicle Transporter & Autophagy Initiator

    RAB2 is part of the RAB family of small GTPases...
  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...

Archives

BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP